Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
117.17
-0.06 (-0.05%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
21,741,189
Open
117.27
Bid (Size)
117.15 (41)
Ask (Size)
117.30 (4)
Prev. Close
117.23
Today's Range
116.41 - 117.50
52wk Range
99.14 - 134.63
Shares Outstanding
2,531,374,696
Dividend Yield
2.49%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Pfizer Advances On Its Cancer Journey
September 20, 2024
On Saturday, Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer cachexia during the European Society for Medical Oncology 2024...
Via
Benzinga
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
September 20, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:MRK),(NYSE:PFE),(NASDAQ:GLMD) EQNX::TICKER_END
Via
FinancialNewsMedia
Performance
YTD
+3.47%
+3.47%
1 Month
+0.49%
+0.49%
3 Month
-11.88%
-11.88%
6 Month
-6.50%
-6.50%
1 Year
+10.70%
+10.70%
More News
Read More
Exploring NYSE:MRK's dividend characteristics.
September 20, 2024
Via
Chartmill
Behind the Scenes of Merck & Co's Latest Options Trends
September 18, 2024
Via
Benzinga
NYSE:MRK: good value for what you're paying.
September 18, 2024
Via
Chartmill
Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry
September 17, 2024
Via
Benzinga
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
September 20, 2024
From
FN Media Group LLC
Via
GlobeNewswire
A Closer Look at 8 Analyst Recommendations For Merck & Co
September 16, 2024
Via
Benzinga
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
September 20, 2024
From
Merck & Co., Inc.
Via
Business Wire
Is It Too Late to Buy ServiceNow Stock?
September 20, 2024
Via
The Motley Fool
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
September 19, 2024
Via
Investor's Business Daily
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
September 18, 2024
Via
Benzinga
Exposures
Product Safety
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.
September 18, 2024
Via
The Motley Fool
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
September 18, 2024
From
Merck & Co., Inc.
Via
Business Wire
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
September 18, 2024
Via
The Motley Fool
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
September 17, 2024
Via
Investor's Business Daily
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
September 17, 2024
Via
Benzinga
Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial
September 17, 2024
From
Daiichi Sankyo
Via
Business Wire
Moderna’s Recent Drop: 4 Reasons Bulls See Opportunity
September 16, 2024
Via
MarketBeat
Exposures
COVID-19
Product Safety
NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges
September 16, 2024
Via
Benzinga
Merck Scores Two Key Victories With Keytruda In Women's Cancers
September 15, 2024
Via
Investor's Business Daily
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
September 15, 2024
From
Merck & Co., Inc.
Via
Business Wire
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
September 15, 2024
From
Merck & Co., Inc.
Via
Business Wire
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
September 14, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
September 14, 2024
From
Merck & Co., Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.